Colletti V, Fiorino F G
ENT Department, University of Verona, Italy.
Acta Otolaryngol. 1999 Mar;119(2):214-8. doi: 10.1080/00016489950181693.
Nine patients with profound bilateral hearing loss received a cochlear implant via the middle fossa. Subjects presented with a bilateral radical mastoidectomy cavity, fibroadhesive otitis media, otosclerosis, autoimmune inner ear disease, previous cranial trauma and genetic prelingual deafness. A classic middle fossa approach was adopted. A small cochleostomy was performed on the most superficial part of the basal turn. A Nucleus CI24M cochlear implant system (Cochlear Corporation) was inserted in four patients, a Lauraflex implant (Philips Hearing Implants) in three patients and a Combi 40 + (Med-el) with double electrode array in two. The receiver-stimulator was positioned in a bone well drilled in the temporal squama and the electrode carrier was inserted in the fenestrated cochlea. Speech perception tests, performed over a period of time ranging from 1 to 6 months after cochlear implant activation, yielded better results than those obtained in postlingually deaf patients operated on via the traditional transmastoid route. Cochlear implant insertion via the middle fossa approach is a technique which is suitable for auditory rehabilitation of subjects with a bilateral radical mastoidectomy cavity, chronic middle ear disease, patients suffering from middle ear malformations, and patients with partial obliteration of the cochlea in the basal turn. However, the main advantage of middle fossa cochleostomy consists in the possibility of stimulating areas of the cochlea, i.e. middle and apical turns, where a greater survival rate of spiral ganglion cells is known to occur. This new approach led to major improvements in speech perception in all patients compared with patients operated on with the transmastoid approach and thus, given the present state of the art, it is the only approach which allows stimulation of the entire cochlea and enables the best auditory outcomes to be achieved in patients with a cochlear implant.
9例双侧重度听力损失患者通过中颅窝接受了人工耳蜗植入。这些受试者存在双侧根治性乳突切除腔、纤维粘连性中耳炎、耳硬化症、自身免疫性内耳疾病、既往颅脑外伤和遗传性语前聋。采用经典的中颅窝入路。在蜗底最表层进行小的蜗开窗。4例患者植入了Nucleus CI24M人工耳蜗系统(科利耳公司),3例患者植入了Lauraflex植入体(飞利浦听力植入公司),2例患者植入了带有双电极阵列的Combi 40 +(美迪乐公司)。将接收器-刺激器置于颞鳞部钻出的骨槽内,电极载体插入开窗的耳蜗中。在人工耳蜗激活后1至6个月的时间段内进行的言语感知测试结果,比通过传统经乳突途径手术的语后聋患者所获得的结果更好。通过中颅窝入路植入人工耳蜗是一种适用于具有双侧根治性乳突切除腔、慢性中耳疾病、中耳畸形患者以及蜗底部分闭塞患者的听觉康复技术。然而,中颅窝蜗开窗的主要优势在于有可能刺激耳蜗的区域,即中回和顶回,已知这些区域有更高的螺旋神经节细胞存活率。与经乳突入路手术的患者相比,这种新方法使所有患者的言语感知有了显著改善,因此,就目前的技术水平而言,它是唯一能够刺激整个耳蜗并使人工耳蜗植入患者获得最佳听觉效果的方法。